Pfizer revealed on Wednesday that it had finally dosed its first patient participating in the Phase 2/3 study examining the efficacy of PF-07321332, an orally administered protease inhibitor antiviral designed to combat COVID-19. The randomized, double-blind trial will enroll approximately 1,140 participants, who will receive PF07321332/ritonavir, or a placebo, orally every 12 hours for five days. Pfizer CEO Albert Bourla weighed in via tweet: Success against #COVID19 will likely require both vaccines & treatments. We’re pleased to share we’ve started a Phase 2/3 study of our oral antiviral candidate—specifically designed to combat SARS-CoV-2—in non-hospitalized, low-risk adults: — AlbertBourla (@AlbertBourla) September 1, 2021 The drug is designed for patients who haven't been hospitalized, but who are symptomatic with COVID but at low risk of seeing it progress to severe disease. Right now, there are no officially approved COVID therapeutics, a fact that podcast host Joe Rogan alluded to in a video where he revealed his COVID diagnosis. According to Pfizer's press release, PF-07321332 is a protease inhibitor, which means it hinders the activity of the main protease enzyme that the SARS-CoV-2 virus requires for replication. https://www.zerohedge.com/covid-19/pfizer-doses-first-patient-phase-23-trial-covid-therapeutic